Filtered By:
Specialty: Infectious Diseases
This page shows you your search results in order of relevance. This is page number 8.
Order by Relevance | Date
Total 742 results found since Jan 2013.
Zika virus persists in the central nervous system and lymph nodes of rhesus monkeys
(NIH/National Institute of Allergy and Infectious Diseases) Zika virus can persist in cerebrospinal fluid (CSF), lymph nodes and colorectal tissue of infected rhesus monkeys for weeks after the virus has been cleared from blood, urine and mucosal secretions, according to a study published online in Cell. The research was led by Dan H. Barouch, M.D., Ph.D., and colleagues at Beth Israel Deaconess Medical Center and Harvard Medical School and was funded in part by the National Institute of Allergy and Infectious Diseases.
Source: EurekAlert! - Infectious and Emerging Diseases - April 28, 2017 Category: Infectious Diseases Source Type: news
Antibodies from Ebola survivor protect mice and ferrets against related viruses
(NIH/National Institute of Allergy and Infectious Diseases) Researchers funded in part by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, have studied the blood of an Ebola survivor, searching for human antibodies that might effectively treat people infected with Ebola virus and those infected with related viruses. The researchers have identified two such antibodies that hold promise as Ebola treatments.
Source: EurekAlert! - Infectious and Emerging Diseases - May 18, 2017 Category: Infectious Diseases Source Type: news
Modified experimental vaccine protects monkeys from deadly malaria
(NIH/National Institute of Allergy and Infectious Diseases) Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, modified an experimental malaria vaccine and showed that it completely protected four of eight monkeys that received it against challenge with the virulent Plasmodium falciparum malaria parasite. In three of the remaining four monkeys, the vaccine delayed when parasites first appeared in the blood by more than 25 days.
Source: EurekAlert! - Infectious and Emerging Diseases - May 22, 2017 Category: Infectious Diseases Source Type: news
Multiple research approaches are key to pandemic preparedness, NIAID officials say
(NIH/National Institute of Allergy and Infectious Diseases) Preparedness in the face of major disease outbreaks can save thousands of lives. A new article by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and colleagues examines the multifaceted nature of effective preparedness and the role that biomedical research plays. Specifically, the article examines three approaches to pandemic preparedness: pathogen-specific work, platform-based technologies, and prototype-pathogen efforts. The article appears online in JAMA.
Source: EurekAlert! - Infectious and Emerging Diseases - October 5, 2017 Category: Infectious Diseases Source Type: news
Three decades of responding to infectious disease outbreaks
(NIH/National Institute of Allergy and Infectious Diseases) In 1984, Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, testified before Congress showing a world map annotated with a single emerging infectious disease threat, HIV/AIDS. Since then, numerous diseases and pathogens were added, providing a powerful visual reminder of infectious diseases around the globe. In an essay in Annals of Internal Medicine, Dr. Fauci reflects on the efforts to address infectious disease outbreaks of the past three decades.
Source: EurekAlert! - Infectious and Emerging Diseases - November 14, 2017 Category: Infectious Diseases Source Type: news
Fighting the flu, year after year
(NIH/National Institute of Allergy and Infectious Diseases) In a New England Journal of Medicine perspective, experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza in Melbourne discuss how the process of preparing seasonal influenza vaccines in eggs may contribute to their limited effectiveness. The authors offer research strategies that might yield more protective vaccine candidates.
Source: EurekAlert! - Infectious and Emerging Diseases - November 29, 2017 Category: Infectious Diseases Source Type: news
Trials show inactivated Zika virus vaccine is safe and immunogenic
(NIH/National Institute of Allergy and Infectious Diseases) The investigational Zika purified inactivated virus (ZPIV) vaccine was well-tolerated and induced an immune response in participants, according to initial results from three Phase 1 clinical trials. Scientists at the Walter Reed Army Institute of Research (WRAIR) are developing the vaccine and leading one of the trials. WRAIR also is co-funding the trials with the National Institute of Allergy and Infectious Diseases, part of NIH. The results will appear in The Lancet.
Source: EurekAlert! - Infectious and Emerging Diseases - December 4, 2017 Category: Infectious Diseases Source Type: news
Gene-based Zika vaccine is safe and immunogenic in healthy adults
(NIH/National Institute of Allergy and Infectious Diseases) Results from two Phase 1 clinical trials show an experimental Zika vaccine developed by government scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is safe and induces an immune response in healthy adults. The findings will be published on Dec. 4 in The Lancet. NIAID is currently leading an international effort to evaluate the investigational vaccine in a Phase 2/2b safety and efficacy trial.
Source: EurekAlert! - Infectious and Emerging Diseases - December 4, 2017 Category: Infectious Diseases Source Type: news
Zika remains a research and public health challenge, say NIAID scientists
(NIH/National Institute of Allergy and Infectious Diseases) The Zika virus has become established in more than 80 countries, infected millions of people, and left many babies with birth defects. Although scientists have made progress in their understanding of the virus, it would be premature to think that the Zika pandemic is now under control and will not reemerge, perhaps more aggressively, say leaders from the National Institute of Allergy and Infectious Diseases in a Journal of Infectious Diseases special supplement.
Source: EurekAlert! - Infectious and Emerging Diseases - December 22, 2017 Category: Infectious Diseases Source Type: news
NIH scientists find microbes on the skin of mice promote tissue healing, immunity
(NIH/National Institute of Allergy and Infectious Diseases) Beneficial bacteria on the skin of lab mice work with the animals' immune systems to defend against disease-causing microbes and accelerate wound healing, according to new research from scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Researchers say untangling similar mechanisms in humans may improve approaches to managing skin wounds and treating other damaged tissues. The study was published online today in Cell.
Source: EurekAlert! - Infectious and Emerging Diseases - January 18, 2018 Category: Infectious Diseases Source Type: news
15 years later, PEPFAR continues to save lives
(NIH/National Institute of Allergy and Infectious Diseases) Experts from the National Institute of Allergy and Infectious Diseases have penned a NEJM perspective recognizing the United States President's Emergency Plan for AIDS Relief (PEPFAR) for 15 years of implementing an innovative program to prevent, treat, and care for persons living with HIV and AIDS. The authors stress that continued support for the State Department program is necessary to ensure an effective global response to the HIV pandemic and other infectious diseases worldwide.
Source: EurekAlert! - Infectious and Emerging Diseases - January 24, 2018 Category: Infectious Diseases Source Type: news
NIH study will assess biomarker as indicator of viral lower respiratory tract infection
(NIH/National Institute of Allergy and Infectious Diseases) A new clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, aims to determine whether low blood levels of the protein procalcitonin can reliably indicate whether a person's lower respiratory tract infection will improve with antibiotic treatment.
Source: EurekAlert! - Infectious and Emerging Diseases - February 13, 2018 Category: Infectious Diseases Source Type: news
Migration and risk of HIV acquisition in Rakai, Uganda: a population-based cohort study
Publication date: Available online 25 February 2018 Source:The Lancet HIV Author(s): Oluwasolape Olawore, Aaron A R Tobian, Joseph Kagaayi, Jeremiah M Bazaale, Betty Nantume, Grace Kigozi, Justine Nankinga, Fred Nalugoda, Gertrude Nakigozi, Godfrey Kigozi, Ronald H Gray, Maria J Wawer, Robert Ssekubugu, John S Santelli, Steven J Reynolds, Larry W Chang, David Serwadda, Mary K Grabowski Background In sub-Saharan Africa, migrants typically have higher HIV prevalence than non-migrants; however, whether HIV acquisition typically precedes or follows migration is unknown. We aimed to investigate the risk of HIV after migration ...
Source: The Lancet HIV - February 26, 2018 Category: Infectious Diseases Source Type: research
NIAID unveils strategic plan for developing a universal influenza vaccine
(NIH/National Institute of Allergy and Infectious Diseases) Developing a universal influenza vaccine -- a vaccine that can provide durable protection for all age groups against multiple strains, including those that might cause a pandemic -- is a priority for the National Institute of Allergy and Infectious Diseases. Writing in the Journal of Infectious Diseases, NIAID officials detail the Institute's new strategic plan for addressing the research areas essential to creating a safe and effective universal influenza vaccine.
Source: EurekAlert! - Infectious and Emerging Diseases - February 28, 2018 Category: Infectious Diseases Source Type: news
NIH experts call for transformative research approach to end tuberculosis
(NIH/National Institute of Allergy and Infectious Diseases) A more intensive biomedical research approach is necessary to control and ultimately eliminate tuberculosis (TB), according to a perspective published in The American Journal of Tropical Medicine and Hygiene. In the article, authors Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, and Robert W. Eisinger, Ph.D., special assistant for scientific projects at NIAID, discuss the need to modernize TB research by applying new diagnostic, therapeutic, and vaccine approaches.
Source: EurekAlert! - Infectious and Emerging Diseases - March 9, 2018 Category: Infectious Diseases Source Type: news
